LEUKEMIA SCREENING MARKET ANALYSIS

Leukemia Screening Market, By Test Type (Complete Blood Count (CBC), Bone Marrow Aspiration and Biopsy, Flow Cytometry, Cytogenetic Analysis, Polymerase Chain Reaction (PCR), Immunophenotyping, and Others), By Disease Type (Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML), Chronic Lymphocytic Leukemia (CLL), Chronic Myeloid Leukemia (CML), and Others), By Age Group (Pediatric, Adult, and Geriatric), By End User (Hospitals and Clinics, Diagnostic Laboratories, Research Institutes, and Others), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

Recent Developments

On June 20, 2023, Exact Sciences Corp., a leading provider of cancer screening and diagnostic tests, announced positive top-line results from the pivotal BLUE-C study. The results show that next-generation Cologuard met all study endpoints and improved every top-line metric, including a 30 percent lower false positive rate, when compared to DeeP-C, the FDA registrational trial for Cologuard.
On June 22, 2023, the Leukemia & Lymphoma Society (LLS) announced that the first patient was dosed in a clinical trial investigating whether a shorter course of combination therapy is less toxic while remaining as effective as the FDA-approved regimen in older patients with newly diagnosed acute myeloid leukemia (AML).
On April 24, 2023, ALERCELL, INC., a life sciences company, announced that it had introduced a molecular leukemia diagnostic platform. LENA Molecular Dx Leukemia Platform is a core group of 12 molecular diagnostic tests specialized in leukemia early diagnostic, treatment guidance, and MRD (Minimal residual disease) monitoring.

Acquisition and partnerships

On March 9, 2023, QIAGEN N.V., a provider of molecular testing solutions, announced it had entered into a strategic partnership with Servier, a global pharmaceutical group, to develop a companion diagnostic test for TIBSOVO, an isocitrate dehydrogenase-1 (IDH1) inhibitor indicated for the treatment of the blood cancer acute myeloid leukemia (AML).
On February 2022, BD, a leading global medical technology company, announced it had completed the acquisition of Cytognos, a privately held company headquartered in Salamanca, Spain, specializing in flow cytometry solutions for blood cancer diagnosis, minimal residual disease (MRD) detection and immune monitoring research for blood diseases.